<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36704819</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-7016</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</Title><ISOAbbreviation>J Cereb Blood Flow Metab</ISOAbbreviation></Journal><ArticleTitle>Blood-CNS barrier dysfunction in amyotrophic lateral sclerosis: Proposed mechanisms and clinical implications.</ArticleTitle><Pagination><StartPage>642</StartPage><EndPage>654</EndPage><MedlinePgn>642-654</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0271678X231153281</ELocationID><Abstract><AbstractText>There is strong evidence for blood-brain and blood-spinal cord barrier dysfunction at the early stages of many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Since impairment of the blood-central nervous system barrier (BCNSB) occurs during the pre-symptomatic stages of ALS, the mechanisms underlying this pathology are likely also involved in the ALS disease process. In this review, we explore how drivers of ALS disease, particularly mitochondrial dysfunction, astrocyte pathology and neuroinflammation, may contribute to BCNSB impairment. Mitochondria are highly abundant in BCNSB tissue and mitochondrial dysfunction in ALS contributes to motor neuron death. Likewise, astrocytes adopt key physical, transport and metabolic functions at the barrier, many of which are impaired in ALS. Astrocytes also show raised expression of inflammatory markers in ALS and ablating ALS-causing transgenes in astrocytes slows disease progression. In addition, key drivers of neuroinflammation, including TAR DNA-binding protein 43 (TDP-43) pathology, matrix metalloproteinase activation and systemic inflammation, affect BCNSB integrity in ALS. Finally, we discuss the translational implications of BCNSB dysfunction in ALS, including the development of biomarkers for disease onset and progression, approaches aimed at restoring BCNSB integrity and <i>in vitro</i> modelling of the neurogliovascular system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinruecke</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1647-4481</Identifier><AffiliationInfo><Affiliation>Edinburgh Medical School, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Cambridge School of Clinical Medicine, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonergan</LastName><ForeName>Rebecca Murphy</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>North Middlesex University Hospital NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvaraj</LastName><ForeName>Bhuvaneish T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Castro</LastName><ForeName>Blanca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dementia Research Institute at The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T000708/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cereb Blood Flow Metab</MedlineTA><NlmUniqueID>8112566</NlmUniqueID><ISSNLinking>0271-678X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">blood-CNS barrier</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>2</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36704819</ArticleId><ArticleId IdType="pmc">PMC10108188</ArticleId><ArticleId IdType="doi">10.1177/0271678X231153281</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erd&#x151; F, Denes L, de Lange E.Age-associated physiological and pathological changes at the blood&#x2013;brain barrier: a review. J Cereb Blood Flow Metab 2017; 37: 4&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363756</ArticleId><ArticleId IdType="pubmed">27837191</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer AM.The Role of the blood brain barrier in neurodegenerative disorders and their treatment. J Alzheimers Dis 2011; 24: 643&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460432</ArticleId></ArticleIdList></Reference><Reference><Citation>Keaney J, Campbell M.The dynamic blood&#x2013;brain barrier. FEBS J 2015; 282: 4067&#x2013;4079.</Citation><ArticleIdList><ArticleId IdType="pubmed">26277326</ArticleId></ArticleIdList></Reference><Reference><Citation>Correale J, Villa A.Cellular elements of the blood-brain barrier. Neurochem Res 2009; 34: 2067&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pubmed">19856206</ArticleId></ArticleIdList></Reference><Reference><Citation>Luissint A, Artus C, Glacial F, et al.. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 2012; 9: 23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542074</ArticleId><ArticleId IdType="pubmed">23140302</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Betsholtz C, Genov&#xe9; G, et al.. Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944627</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeten KM, Akassoglou K.Extracellular matrix and matrix receptors in blood&#x2013;brain barrier formation and stroke. Dev Neurobiol 2011; 71: 1018&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482610</ArticleId><ArticleId IdType="pubmed">21780303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Pachter JS.Isolation and culture of microvascular endothelial cells from murine spinal cord. J Neuroimmunol 2006; 177: 209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">16806499</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell HL, Kersch CN, Woltjer RL, et al.. The Translational significance of the neurovascular unit. J Biol Chem 2017; 292: 762&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5247651</ArticleId><ArticleId IdType="pubmed">27920202</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F.Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 2019; 32: 771&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, et al.. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 2019; 13: 1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav A, Matson K, Li L, et al.. A cellular taxonomy of the adult human spinal cord. bioRxiv. 2022. 10.1101/2022.03.25.485808.</Citation></Reference><Reference><Citation>Kakaroubas N, Brennan S, Keon M, et al.. Pathomechanisms of blood-brain barrier disruption in ALS. Neurosci J 2019; 2019: 2537698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6652091</ArticleId><ArticleId IdType="pubmed">31380411</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, et al.. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013; 29: 499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, et al.. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet 2017; 26: 4093&#x2013;4094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886132</ArticleId><ArticleId IdType="pubmed">28973528</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM.C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 2018; 14: 544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafuri F, Ronchi D, Magri F, et al.. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front Cell Neurosci 2015; 9: 336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548205</ArticleId><ArticleId IdType="pubmed">26379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen H, Shaw CE.TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics 2015; 12: 352&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F, Maduro C, Fisher EMC, et al.. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis Model Mech 2019; 12: 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361152</ArticleId><ArticleId IdType="pubmed">30626575</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J, Gregory-Evans C, Shaw C.Animal models of amyotrophic lateral sclerosis: a comparison of model validity. Neural Regen Res 2018; 13: 2050&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW.Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009; 187: 761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH, Benn S, Yamamoto TH, et al.. Corticospinal motor neurons and related subcerebral projection neurons undergo early and specific neurodegeneration in hSOD1G93A transgenic ALS mice. J Neurosci 2011; 31: 4166&#x2013;4177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643523</ArticleId><ArticleId IdType="pubmed">21411657</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J.Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2019; 20: 303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP.Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci 2020; 417: 117054.</Citation><ArticleIdList><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Rodrigues MCO, Hernandez-Ontiveros DG, et al.. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res 2011; 1398: 113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, et al.. Blood&#x2013;spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A 2014; 111: 3912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Argaw AT, Asp L, Zhang J, et al.. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012; 122: 2454&#x2013;2468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386814</ArticleId><ArticleId IdType="pubmed">22653056</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman R, Prat A.The blood-brain barrier. Cold Spring Harb Perspect Biol 2015; 7: a020412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4292164</ArticleId><ArticleId IdType="pubmed">25561720</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi A, Abbruzzese G, Arata L, et al.. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 1984; 231: 75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">6737012</ArticleId></ArticleIdList></Reference><Reference><Citation>Annunziata P, Volpi N.High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol Scand 1985; 72: 61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">4050318</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H.Deposits of IgG and C 3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984; 6: 51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, et al.. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004; 55: 221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH.Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993; 50: 30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Haller E, et al.. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2007; 2: e1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MC, Couch Y, Sibson N, et al.. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013; 53: 34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, et al.. Ultrastructure of blood&#x2013;brain barrier and blood&#x2013;spinal cord barrier in SOD1 mice modeling ALS. Brain Res 2007; 1157: 126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Sagare A, Ali Z, et al.. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 2008; 11: 420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al.. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 2009; 72: 1614&#x2013;1616.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Woods RL, Louis MK, et al.. Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS One 2010; 5: e1061410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868893</ArticleId><ArticleId IdType="pubmed">20485543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Sagare AP, et al.. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056408</ArticleId><ArticleId IdType="pubmed">21040844</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulou AM, Montagne A, Kisler K, et al.. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci 2019; 22: 1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668719</ArticleId><ArticleId IdType="pubmed">31235908</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamadera M, Fujimura H, Inoue K, et al.. Microvascular disturbance with decreased pericyte coverage is prominent in the ventral horn of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 393&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">25740316</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, et al.. Blood&#x2013;spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol 2013; 125: 111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MCO, et al.. Impaired blood&#x2013;brain/spinal cord barrier in ALS patients. Brain Res 2012; 1469: 114&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, et al.. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res 2011; 89: 718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Batavelji&#x107; D, Nikoli&#x107; L, Milosevi&#x107; M, et al.. Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1G93A rat model. Glia 2012; 60: 1991&#x2013;2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">22987392</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ.The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 2019; 710: 132933.</Citation><ArticleIdList><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldendorf WH, Cornford ME, Brown WJ.The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1977; 1: 409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">617259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Xu Z.Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18: 3241&#x2013;3250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M.Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007; 66: 10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Yang M, Chen Y, et al.. FUS Interacts with HSP60 to promote mitochondrial damage. PLoS Genet 2015; 11: e1005357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559378</ArticleId><ArticleId IdType="pubmed">26335776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Gregory JM, Dando O, et al.. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol 2021; 141: 257&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S, Ait-El-Mkadem S, Verschueren A, et al.. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014; 137: 2329&#x2013;2345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll D, Hu H, Sun J, et al.. Mitochondrial crisis in cerebrovascular endothelial cells opens the blood&#x2013;brain barrier. Stroke 2015; 46: 1681&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4418219</ArticleId><ArticleId IdType="pubmed">25922503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukeirat M, Sarkar SN, Hu H, et al.. MiR-34a regulates blood&#x2013;brain barrier permeability and mitochondrial function by targeting cytochrome c. J Cereb Blood Flow Metab 2016; 36: 387&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759667</ArticleId><ArticleId IdType="pubmed">26661155</ArticleId></ArticleIdList></Reference><Reference><Citation>Haileselassie B, Joshi AU, Minhas PS, et al.. Mitochondrial dysfunction mediated through dynamin-related protein 1 (Drp1) propagates impairment in blood brain barrier in septic encephalopathy. J Neuroinflammation 2020; 17: 36&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986002</ArticleId><ArticleId IdType="pubmed">31987040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W, Zhang Y, Jiao Y, et al.. Dexmedetomidine maintains blood&#x2013;brain barrier integrity by inhibiting Drp1-related endothelial mitochondrial dysfunction in ischemic stroke. Acta Biochim Biophys Sin (Shanghai) 2021; 53: 1177&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">34244711</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU, Saw NL, Vogel H, et al.. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol Med 2018; 10: 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840540</ArticleId><ArticleId IdType="pubmed">29335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani L, Eckert A.Amyloid-beta interaction with mitochondria. Int J Alzheimers Dis 2011; 2011: 925050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065051</ArticleId><ArticleId IdType="pubmed">21461357</ArticleId></ArticleIdList></Reference><Reference><Citation>Haorah J, Knipe B, Leibhart J, et al.. Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. J Leukoc Biol 2005; 78: 1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">16204625</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun PBL, Lu J, Moochhala S.Involvement of ROS in BBB dysfunction. Free Radic Res 2009; 43: 348&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">19241241</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, Heneka MT.Danger&#x2010;associated molecular patterns in Alzheimer&#x2019;s disease. J Leukoc Biol 2017; 101: 87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28049142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner P, Stephenson D, Wright S.Reactive astrogliosis is widespread in the subcortical white matter of amyotrophic lateral sclerosis brain. J Neuropathol Exp Neurol 1991; 50: 263&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">2022968</ArticleId></ArticleIdList></Reference><Reference><Citation>Maih&#xf6;fner C, Probst-Cousin S, Bergmann M, et al.. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003; 18: 1527&#x2013;1534.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511332</ArticleId></ArticleIdList></Reference><Reference><Citation>Anneser JMH, Cookson MR, Ince PG, et al.. Glial cells of the spinal cord and subcortical white matter up-regulate neuronal nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp Neurol 2001; 171: 418&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">11573993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Becher MW, Lee MK, et al.. ALS-Linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Gutmann DH, Roos RP.Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet 2011; 20: 286&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Haidet-Phillips AM, Hester ME, et al.. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011; 29: 824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis NJ, Lepore AC, Rauck B, et al.. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 2008; 11: 1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656686</ArticleId><ArticleId IdType="pubmed">18931666</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ, R&#xf6;nnb&#xe4;ck L, Hansson E.Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi Y, Utsumi H, Chiba H, et al.. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood&#x2013;brain barrier. Biochem Biophys Res Commun 1999; 261: 108&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10405331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendfeldt K, Radojevic V, Kapfhammer J, et al.. Basic fibroblast growth factor modulates density of blood vessels and preserves tight junctions in organotypic cortical cultures of mice: a new in vitro model of the blood-brain barrier. J Neurosci 2007; 27: 3260&#x2013;3267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672460</ArticleId><ArticleId IdType="pubmed">17376986</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet EA, Iyer AM, Mesarosova L, et al.. Expression and cellular distribution of P-Glycoprotein and breast cancer resistance protein in amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 2020; 79: 266&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036662</ArticleId><ArticleId IdType="pubmed">31999342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko K, Atsumi T, Miyataka T.The excessive activity of cytochrome P450 system in ALS &#x2013; the metabolic ratio of sparteine. Rinsho Shinkeigaku 1989; 29: 1251&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pubmed">2605831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh C, Puvenna V, Gonzalez-Martinez J, et al.. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr Drug Metab 2011; 12: 742&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4874186</ArticleId><ArticleId IdType="pubmed">21568937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV.Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 2015; 16: 249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Horng S, Therattil A, Moyon S, et al.. Astrocytic tight junctions control inflammatory CNS lesion pathogenesis. J Clin Invest 2017; 127: 3136&#x2013;3151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5531407</ArticleId><ArticleId IdType="pubmed">28737509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jin S, Sonobe Y, et al.. Interleukin-1&#x3b2; induces blood-brain barrier disruption by downregulating sonic hedgehog in astrocytes. PLoS One 2014; 9: e110024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196962</ArticleId><ArticleId IdType="pubmed">25313834</ArticleId></ArticleIdList></Reference><Reference><Citation>Acaz-Fonseca E, Ortiz-Rodriguez A, Azcoitia I, et al.. Notch signaling in astrocytes mediates their morphological response to an inflammatory challenge. Cell Death Discov 2019; 5: 85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447583</ArticleId><ArticleId IdType="pubmed">30962951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Takanashi Y, Sugita K, et al.. Endogenous reactive oxygen species cause astrocyte defects and neuronal dysfunctions in the hippocampus: a new model for aging brain. Aging Cell 2017; 16: 39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242301</ArticleId><ArticleId IdType="pubmed">27623715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson E, R&#xf6;nnb&#xe4;ck L.Astrocytic receptors and second messenger systems. Adv Mol Cell Biol 2003; 31: 475&#x2013;501.</Citation></Reference><Reference><Citation>Vazana U, Veksler R, Pell GS, et al.. Glutamate-mediated blood-brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci 2016; 36: 7727&#x2013;7739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4951577</ArticleId><ArticleId IdType="pubmed">27445149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bal-Price A, Moneer Z, Brown GC.Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes. Glia 2002; 40: 312&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Schousboe A, Scafidi S, Bak LK, et al.. Glutamate metabolism in the brain focusing on astrocytes. Adv Neurobiol 2014; 11: 13&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667713</ArticleId><ArticleId IdType="pubmed">25236722</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al.. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V.A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M, Lee S, Jeon Y, et al.. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med 2020; 52: 1652&#x2013;1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080625</ArticleId><ArticleId IdType="pubmed">33051572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Andr&#xe9;s-Benito P, Carmona M, et al.. TDP-43 vasculopathy in the spinal cord in sporadic amyotrophic lateral sclerosis (sALS) and frontal cortex in sALS/FTLD-TDP. J Neuropathol Exp Neurol 2021; 80: 229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899266</ArticleId><ArticleId IdType="pubmed">33421065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim S, Kang H, et al.. The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response. J Neuroinflammation 2020; 17: 299299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556969</ArticleId><ArticleId IdType="pubmed">33054766</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, et al.. Elevated IL-6 and TNF-&#x3b1; levels in patients with ALS: inflammation or hypoxia? Neurology 2005; 65: 1958&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamudio F, Loon AR, Smeltzer S, et al.. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. J Neuroinflammation 2020; 17: 283283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519496</ArticleId><ArticleId IdType="pubmed">32979923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, Gautam M, Kocak N, et al.. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J Neuroinflammation 2019; 16: 196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6822373</ArticleId><ArticleId IdType="pubmed">31666087</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukaszewicz-Zaj&#x105;c M, Mroczko B, S&#x142;owik A.Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS). J Neural Transm (Vienna) 2014; 121: 1387&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4210652</ArticleId><ArticleId IdType="pubmed">25047909</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ, Petersen RC.Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 2018; 128: 1208&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873891</ArticleId><ArticleId IdType="pubmed">29457783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Estrada EY, Thompson JF, et al.. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">16850029</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Khan T, Dominique MA, et al.. Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice. Neurobiol Dis 2019; 124: 133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053168</ArticleId><ArticleId IdType="pubmed">30458231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A, Spiller KJ, Towne C, et al.. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 2014; 81: 333&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015650</ArticleId><ArticleId IdType="pubmed">24462097</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Wu C, Korpos E, et al.. Focal MMP-2 and MMP-9 activity at the blood-brain barrier promotes chemokine-induced leukocyte migration. Cell Rep 2015; 10: 1040&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin X, et al.. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep 2017; 7: 9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Rogowski O, Berliner S, et al.. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119: 383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, et al.. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 2017; 74: 660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, et al.. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol 2017; 74: 1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea I.The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol 2021; 18: 2489&#x2013;2501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481764</ArticleId><ArticleId IdType="pubmed">34594000</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Holmes C.Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014; 10: 217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">24638131</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A, Galea I.The blood-brain barrier in systemic inflammation. Brain Behav Immun 2017; 60: 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26995317</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia AS, Patel P, Dutta K, et al.. Inflammation induces TDP-43 mislocalization and aggregation. PLoS One 2015; 10: e0140248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596857</ArticleId><ArticleId IdType="pubmed">26444430</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Jardel C, Salachas F, et al.. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2016; 17: 404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">27415180</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhu G, Wang X, et al.. Anterior thalamic nuclei deep brain stimulation reduces disruption of the blood-brain barrier, albumin extravasation, inflammation and apoptosis in kainic acid-induced epileptic rats. Neurol Res 2017; 39: 1103&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">28918702</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Min J, Huang W, et al.. Vitexin reduces epilepsy after hypoxic ischemia in the neonatal brain via inhibition of NKCC1. J Neuroinflammation 2018; 15: 186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6011387</ArticleId><ArticleId IdType="pubmed">29925377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongnok B, Khuanjing T, Chunchai T, et al.. Donepezil provides neuroprotective effects against brain injury and Alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury. Biochim Biophys Acta Mol Basis Dis 2021; 1867: 165975.</Citation><ArticleIdList><ArticleId IdType="pubmed">32956775</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekaart DWM, Bertran A, Jia S, et al.. The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects. J Clin Invest 2021; 131: 1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773344</ArticleId><ArticleId IdType="pubmed">33141761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, et al.. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008; 28: 13574&#x2013;13581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, et al.. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep 2015; 11: 592&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Ilieva H, Hallagan L, et al.. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009; 119: 3437&#x2013;3449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769191</ArticleId><ArticleId IdType="pubmed">19841542</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Hung S, Rocha G, et al.. Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight 2019; 5: 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693831</ArticleId><ArticleId IdType="pubmed">31310593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Chung M, Lee S, et al.. 3D brain angiogenesis model to reconstitute functional human blood&#x2013;brain barrier in vitro. Biotechnol Bioeng 2020; 117: 748&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">31709508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SI, Sei YJ, Park H, et al.. Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms. Nat Commun 2020; 11: 175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954233</ArticleId><ArticleId IdType="pubmed">31924752</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman MJ, Svendsen CN.Recent advances in human iPSC-derived models of the blood-brain barrier. Fluids Barriers CNS 2020; 17: 30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178976</ArticleId><ArticleId IdType="pubmed">32321511</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H, Lichter J, Sarlo M, et al.. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia 2016; 64: 1298&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541958</ArticleId><ArticleId IdType="pubmed">27158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan GNY, Evans RA, Banks DB, et al.. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model. Neurosci Lett 2017; 639: 103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5278641</ArticleId><ArticleId IdType="pubmed">28011392</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>